Risk of Ventricular Arrhythmia and Sudden Cardiac Arrest Among Older Patients Using Lamotrigine for Epilepsy [0.03%]
老年癫痫患者使用拉莫三嗪的风险及突发性心脏骤停事件
Gloria Y F Ho,Daniel B Horton,Parin J Patel et al.
Gloria Y F Ho et al.
We identified new users of lamotrigine and levetiracetam without inpatient or emergency VA/SCA diagnosis in the 12-month continuous enrollment baseline period before initiation of treatment.
Real-World Harm Reduction of Metformin Plus DPP4 Inhibitors versus Metformin Plus Sulfonylureas in Older Adults: A Target Trial Emulation Using German Claims Data [0.03%]
二甲双胍联合DPP4抑制剂与二甲双胍联合磺脲类药物在老年人群中的实际获益减风险性：利用德国保险理赔数据的靶标试验模拟研究
Paula Starke,Petra Thürmann,Thomas Grobe et al.
Paula Starke et al.
In contrast, we found a protective effect of DPP4i on the risk for severe hypoglycemia in the subgroups of new users (ratio rate (RR) = 0.51, 95% CI 0.33, 0.76) and patients with severe renal insufficiency (RR = 0.31, 95% CI 0.16, 0.61).
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide-1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohorts Retrospective Study [0.03%]
二甲双胍继代药物SGLT2抑制剂与GLP-1受体激动剂对2型糖尿病患者骨关节炎及关节置换术风险的影响：倾向性匹配队列回顾性研究
Yu-Chi Su,Pei-Chun Hsieh,Edward Chia-Cheng Lai et al.
Yu-Chi Su et al.
This study compared the risks of new-onset osteoarthritis and joint replacement surgery between new users of SGLT2is and new users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)....First, new users of SGLT2is and GLP-1 RAs among patients with type 2 diabetes mellitus were identified. Two homogeneous groups were established through propensity score matching. The study outcomes were the risks of new-onset osteoarthritis and joint replacement surgery of the hip or knee.
Comparative Study
Diabetes/metabolism research and reviews. 2025 Jul;41(5):e70051. DOI:10.1002/dmrr.70051 2025
Changes in nationwide thyroid hormone replacement use during the pandemic: results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) Study [0.03%]
土耳其新冠疫情期间全国甲状腺激素替代治疗变化：来自“新冠大流行下土耳其药物利用趋势研究”(PANDUTI-TR)的结果
Caner Vizdiklar,Volkan Aydin,Onur Gultekin et al.
Caner Vizdiklar et al.
Projected prescribing for new users remained stable across three periods (p > 0.05). This study demonstrated that THP utilization showed a modest upward trend since the onset of the COVID-19 pandemic.
Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes [0.03%]
GLP-1受体激动剂与2型糖尿病患者胃肠道癌症风险的关系
Chia-Chih Kuo,Min-Hsiang Chuang,Chun-Hsien Li et al.
Chia-Chih Kuo et al.
Methods: Using the TriNetX Research Network, we conducted a retrospective cohort study comparing new users of GLP-1RAs with users of other glucose-lowering medications.
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study [0.03%]
GLP-1受体激动剂的甲状腺肿瘤风险：一项回顾性队列研究
Daniel R Morales,Fan Bu,Benjamin Viernes et al.
Daniel R Morales et al.
Participants included patients with type 2 diabetes mellitus (T2DM) with prior metformin therapy initiating a GLP-1RA versus new users of sodium-glucose cotransporter 2 inhibitors (SGLT2is), dipeptidyl peptidase 4 inhibitors (DPP-4is), and sulfonylureas (SUs).
Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease [0.03%]
新诊断2型糖尿病合并慢性肾脏病患者使用SGLT2抑制剂或GLP-1受体激动剂的转归：倾向评分匹配队列研究
J Bradley Layton,Ryan Ziemiecki,Catherine B Johannes et al.
J Bradley Layton et al.
Methods: Data describing adults (≥ 18 years) with T2D and CKD who were new users of either SGLT2i or GLP-1 RA from 2012 to 2019 were assessed from population-based Danish National Health Registers (DNHR) and Valencia Health System Integrated Database (VID), hospital-based Japan Chronic
Overall Uptake and Racial, Ethnic, and Socioeconomic Disparities in the Use of Continuous Glucose Monitoring Devices Among Insulin-Treated Older Adults With Type 2 Diabetes [0.03%]
2型糖尿病老年胰岛素治疗患者持续葡萄糖监测装置的整体使用情况及其种族、民族和社会经济差异
Wajd Alkabbani,Sara J Cromer,Dae Hyun Kim et al.
Wajd Alkabbani et al.
Then, we 1:4 matched new users of CGM to patients unexposed to CGM, using risk set sampling. Index date was the date of CGM initiation or, for control participants, the closest physician visit within ±7 days.
Comparative Effectiveness of TNF-α and IL-6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study [0.03%]
一项关于类风湿关节炎患者的肿瘤坏死因子α和白细胞介素6抑制剂对骨健康结局及死亡率影响的回顾性队列研究：比较疗效分析
Hong Wang,Yun-Hen Lee,I-Han Cheng et al.
Hong Wang et al.
The adult patients diagnosed with Rheumatoid Arthritis (RA) were identified and divided into two groups of new users of TNF-α and IL-6 inhibitors. Patients with prior fractures or who switched treatments post-index were excluded.
PTPN2 and Leukopenia in Individuals With Normal TPMT and NUDT15 Metabolizer Status Taking Azathioprine [0.03%]
PTPN2和Azathioprine诱发的中性粒细胞减少症之间的关联及其在TPMT和NUDT15正常代谢表型个体中的作用
Laura L Daniel,Puran Nepal,Jacy Zanussi et al.
Laura L Daniel et al.
Using BioVU, Vanderbilt's electronic health record linked to genetic data, we assembled a discovery cohort of new users of azathioprine. The analysis was conducted in 1184 new users of azathioprine who had no history of prior thiopurine use or an organ transplant.
耗时 0.19956 秒，为您在
48223910
条记录里面共找到 2030 篇文章 [XML]